Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 39

Sort by

Sort Order Select

Journal Articles

Indolent Lymphoma and Vitamin D (ILyAD): A Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Supplemental Effect of Vitamin D on Event-Free Survival in Patients with Low Tumor Burden Indolent Non-Hodgkin Lymphoma Treated with Rituximab

Jonathan W. Friedberg, MD, Michael T. Brady, PhD, Myla Strawderman, MS, Brad S. Kahl, MD, John P. Leonard, MD, Izidore S. Lossos, MD, Christopher R. Flowers, MD MS, Grerk Sutamtewagul, MD, Jonathon B. Cohen, MDMS, Derick R. Peterson, PhD, Loretta J. Nastoupil, MD MSc

Blood (2019) 134 (Supplement_1): 4008.

https://doi.org/10.1182/blood-2019-127320

Published: 2019

Journal Articles

Cellular Kinetics and Anti-Therapeutic Antibody in Relapsed/Refractory B-NHL Patients Treated with JWCAR029

Zhitao Ying, MD PhD, Pengpeng Xu, MD, Ming Hao, PhD, Li Wang, MD PhD, Shu Cheng, MD PhD, Wen Wu, MD PhD, Wen Wang, MD PhD, Zisong Zhou, Su Yang, Jennifer Wang, PhD, Harry Lam, PhD, James Li, Hongxia Zheng, MD PhD, Weili Zhao, MD PhD, Yuqin Song, MD PhD, Jun Zhu, BS

Blood (2019) 134 (Supplement_1): 4083.

https://doi.org/10.1182/blood-2019-126408

Published: 2019

Journal Articles

Surface Density of CAR Molecules May Modulate the Kinetics of CAR-T Cells In Vivo

Jianqiang Li, PhD, Jin-Yuan Ho, PhD, Lin Wang, Xing Niu, Min Ba, Qinglong Wang, Junfang Yang, MD, Xian Zhang, MD, Dandan Chen, Peihua Lu

Blood (2019) 134 (Supplement_1): 54.

https://doi.org/10.1182/blood-2019-125467

Published: 2019

Journal Articles

Anti-CD6 Monoclonal Antibody Itolizumab Efficiently Inhibits T Cell Proliferation after in Vitro TCR Stimulation in the Setting of Acute Graft Versus Host Disease

Benedetta Rambaldi, MD, Carol Reynolds, PhD, Sharmila Chamling Rai, BSc, Takeru Asano, MD PhD, Yohei Arihara, MD PhD, Mahasweta Gooptu, MD, John Koreth, MBBS, DPhil, Corey Cutler, MD MPH, FRCPC, Sarah Nikiforow, MD PhD, Vincent T. Ho, MD, Edwin P. Alyea, III, MD, Joseph H. Antin, MD, Rizwan Romee, MD PhD, Robert J. Soiffer, MD, Domenico Russo, MD, Jeanette Ampudia, BSc, Cherie Tracy Ng, PhD MPH, Stephen Connelly, PhD MBA, Jerome Ritz, MD

Blood (2019) 134 (Supplement_1): 4517.

https://doi.org/10.1182/blood-2019-125721

Published: 2019

Journal Articles

Targeted Alpha Therapy with 212Pb-NNV003 for the Treatment of CD37 Positive B-Cell Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin Lymphoma (NHL)

Amal Saidi, PhD, Astri Maaland, Julien Torgue, PhD, Helen Heyerdahl, PhD, Jostein Dahle, PhD

Blood (2018) 132 (Supplement 1): 4422.

https://doi.org/10.1182/blood-2018-99-110297

Published: 2018

Journal Articles

Combination Treatment with 5F9 and Azacitidine Enhances Phagocytic Elimination of Acute Myeloid Leukemia

Dongdong Feng, PhD, Phung Gip, PhD, Kelly Marie McKenna, BS, Feifei Zhao, Ofelia Mata, Timothy S Choi, BS, Jiaqi Duan, MS, Kavitha Sompalli, MS, Ravi Majeti, MD PhD, Irving L Weissman, MD, Chris H Takimoto, MD PhD, Mark Ping Chao, MD PhD, James Y Chen, MD PhD, Jie Liu, PhD MD, Jens-Peter Volkmer, MD

Blood (2018) 132 (Supplement 1): 2729.

https://doi.org/10.1182/blood-2018-99-120170

Published: 2018

Journal Articles

CD19-Specific Chimeric Antigen Receptor-Modified T Cells with Safety Switch Produced Under "Point-of-Care" Using the Sleeping Beauty System for the Very Rapid Manufacture and Treatment of B-Cell Malignancies

Tim Chan, PhD, John Gallagher, Nai-Lin Cheng, PhD, Fernando Carvajal-Borda, DVM, Jacques Plummer, Adeline Govekung, John A Barrett, PhD, Pranay D. Khare, PhD, Laurence J N Cooper, MDPhD, Rutul R Shah

Blood (2017) 130 (Supplement 1): 1324.

https://doi.org/10.1182/blood.V130.Suppl_1.1324.1324

Published: 2017

Journal Articles

Engineering Precision Medicine to Enhance Graft-Versus-Lymphoma Activity: Hematopoietic Stem Cells Modified with Chimeric Antigen Receptors

Roy L Kao, MD, Laurel C Truscott, MD, Tzu-Ting Chiou, PhD, Satiro N. De Oliveira, MD

Blood (2017) 130 (Supplement 1): 2064.

https://doi.org/10.1182/blood.V130.Suppl_1.2064.2064

Published: 2017

Journal Articles

Genetically Engineered Pluripotent Cell-Derived Natural Killer Cell Therapy Provides Enhanced Antibody Dependent Cellular Cytotoxicity Against Hematologic Malignancies and Solid Tumors in Combination with Monoclonal Antibody Therapy

Huang Zhu, PhD, Ryan Bjordahl, PhD, Svetlana Gaidarova, Paul Rogers, Robert Blum, Dan Kaufman, MD, Bruce Walcheck, PhD, Bahram Valamehr, PhD

Blood (2017) 130 (Supplement 1): 4452.

https://doi.org/10.1182/blood.V130.Suppl_1.4452.4452

Published: 2017

Journal Articles

Development and Evaluation of a Human Single Chain Variable Fragment (scFv) Derived Bcma Targeted CAR T Cell Vector Leads to a High Objective Response Rate in Patients with Advanced MM

Blood (2017) 130 (Supplement 1): 742.

https://doi.org/10.1182/blood.V130.Suppl_1.742.742

Published: 2017

Journal Articles

Autologous T Cells Modified to Co-Express CD33-Specific Chimeric Antigen Receptor and a Kill Switch for Treatment of CD33 + Acute Myeloid Leukemia

Degang Song, PhD, Michael H Swartz, Linhua Tian, Fernando Carvajal-Borda, DVM, Jacques Plummer, Rutul R Shah, William G Wierda, MD PhD, Laurence J N Cooper, MDPhD, Tim Chan, PhD

Blood (2017) 130 (Supplement 1): 1376.

https://doi.org/10.1182/blood.V130.Suppl_1.1376.1376

Published: 2017

Journal Articles

CD33-Directed Chimeric Antigen Receptor (CAR) T Cells for the Treatment of Acute Myeloid Leukemia (AML)

Sarwish Rafiq, PhD, Terence J. Purdon, Liora M. Schultz, MD, Renier J. Brentjens, MD PhD

Blood (2016) 128 (22): 2825.

https://doi.org/10.1182/blood.V128.22.2825.2825

Published: 2016

Journal Articles

Effects of Chemotherapy on Extracellular Vesicles and Coagulation Activation in Colorectal Cancer Patients: A Pilot Study

Ludwig Traby, MD, Hannah C. Puhr, Marietta Kollars, Kammer Michael, Gerald Prager, MD, Werner Scheithauer, MD, Gabriela Kornek, MD, Paul Alexander Kyrle, MD, Sabine Eichinger, MD

Blood (2016) 128 (22): 1425.

https://doi.org/10.1182/blood.V128.22.1425.1425

Published: 2016

Journal Articles

Multiplexed Engineering of CD19CAR T Cells for Post-Transplant Consolidative Immunotherapy

Corinne Summers, MD, Alexandra Grier, Rebecca Gardner, MD, Colleen Delaney, MD MSc, Michael C Jensen, MD

Blood (2016) 128 (22): 1159.

https://doi.org/10.1182/blood.V128.22.1159.1159

Published: 2016

Journal Articles

Chimeric Antigen Receptor-Modified T Cells for the Treatment of Acute Myeloid Leukemia Expressing CD33

Degang Song, PhD, Michael H. Swartz, Steve G. Biesecker, Fernando Borda, Rutul R. Shah, Peter Emtage, PhD, William G. Wierda, MD PhD, Laurence J.N. Cooper, MD PhD, Tim Chan, PhD

Blood (2016) 128 (22): 4058.

https://doi.org/10.1182/blood.V128.22.4058.4058

Published: 2016

Journal Articles

Critical Analysis on the Mechanism of Action (MoA) of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma (MM)

Laura Moreno, Aintzane Zabaleta, Diego Alignani, Daniel Ajona, Marta Lasa, Patricia Maiso, PhD, Tomas Jelinek, MD, Victor Segura, PhD, Jose Antonio Delgado, Paula Rodriguez-Otero, MD PhD, Felipe Prosper, MD, Jesus San Miguel, MD PhD, Bruno Paiva, PhD

Blood (2016) 128 (22): 2105.

https://doi.org/10.1182/blood.V128.22.2105.2105

Published: 2016

Journal Articles

Gene Modification of Human Hematopoietic Stem Cells with Suicide Genes As a Safety Control

Laurel Christine Truscott, MD, Tzu Ting Chiou, PhD, Roy L. Kao, MD, Satiro N. De Oliveira, MD

Blood (2016) 128 (22): 5888.

https://doi.org/10.1182/blood.V128.22.5888.5888

Published: 2016

Journal Articles

Choice of Better T-cells for Adoptive Immunotherapy

Dirk Hans Busch, MD

Blood (2015) 126 (23): SCI-22.

https://doi.org/10.1182/blood.V126.23.SCI-22.SCI-22

Published: 2015

Journal Articles

Natural Killer Cells Activated By Oncolytic Reovirus Enhance Cetuximab Mediated Antibody Dependent Cellular Cytotoxicity in an in Vitro and In Vivo Model of Colorectal Cancer

Xing Zhao, PhD, Narendiran Rajasekaran, PhD, Cariad Chester, BA, Atsushi Yonezawa, PhD, Suparna Dutt, PhD, Matt Coffey, Zhixu He, MDPhD, Holbrook E Kohrt, MD PhD

Blood (2015) 126 (23): 3439.

https://doi.org/10.1182/blood.V126.23.3439.3439

Published: 2015

Journal Articles

Switching from IgG1 to IgG3 Isotype to Boost Complement-Activating Capacities of Therapeutic Antibodies – Impact of CD55 Expression on the Mode of Action

Stefanie Derer, PhD, Thies Rösner, Stefan Lohse, PhD, Matthias Peipp, PhD, Thomas Valerius, MD

Blood (2014) 124 (21): 3506.

https://doi.org/10.1182/blood.V124.21.3506.3506

Published: 2014

NARROW

Indolent Lymphoma and Vitamin D (ILyAD): A Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Supplemental Effect of Vitamin D on Event-Free Survival in Patients with Low Tumor Burden Indolent Non-Hodgkin Lymphoma Treated with Rituximab

Cellular Kinetics and Anti-Therapeutic Antibody in Relapsed/Refractory B-NHL Patients Treated with JWCAR029

Surface Density of CAR Molecules May Modulate the Kinetics of CAR-T Cells In Vivo

Anti-CD6 Monoclonal Antibody Itolizumab Efficiently Inhibits T Cell Proliferation after in Vitro TCR Stimulation in the Setting of Acute Graft Versus Host Disease

Targeted Alpha Therapy with 212Pb-NNV003 for the Treatment of CD37 Positive B-Cell Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin Lymphoma (NHL)

Combination Treatment with 5F9 and Azacitidine Enhances Phagocytic Elimination of Acute Myeloid Leukemia

CD19-Specific Chimeric Antigen Receptor-Modified T Cells with Safety Switch Produced Under "Point-of-Care" Using the Sleeping Beauty System for the Very Rapid Manufacture and Treatment of B-Cell Malignancies

Engineering Precision Medicine to Enhance Graft-Versus-Lymphoma Activity: Hematopoietic Stem Cells Modified with Chimeric Antigen Receptors

Genetically Engineered Pluripotent Cell-Derived Natural Killer Cell Therapy Provides Enhanced Antibody Dependent Cellular Cytotoxicity Against Hematologic Malignancies and Solid Tumors in Combination with Monoclonal Antibody Therapy

Development and Evaluation of a Human Single Chain Variable Fragment (scFv) Derived Bcma Targeted CAR T Cell Vector Leads to a High Objective Response Rate in Patients with Advanced MM

Autologous T Cells Modified to Co-Express CD33-Specific Chimeric Antigen Receptor and a Kill Switch for Treatment of CD33 + Acute Myeloid Leukemia

CD33-Directed Chimeric Antigen Receptor (CAR) T Cells for the Treatment of Acute Myeloid Leukemia (AML)

Effects of Chemotherapy on Extracellular Vesicles and Coagulation Activation in Colorectal Cancer Patients: A Pilot Study

Multiplexed Engineering of CD19CAR T Cells for Post-Transplant Consolidative Immunotherapy

Chimeric Antigen Receptor-Modified T Cells for the Treatment of Acute Myeloid Leukemia Expressing CD33

Critical Analysis on the Mechanism of Action (MoA) of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma (MM)

Gene Modification of Human Hematopoietic Stem Cells with Suicide Genes As a Safety Control

Choice of Better T-cells for Adoptive Immunotherapy

Natural Killer Cells Activated By Oncolytic Reovirus Enhance Cetuximab Mediated Antibody Dependent Cellular Cytotoxicity in an in Vitro and In Vivo Model of Colorectal Cancer

Switching from IgG1 to IgG3 Isotype to Boost Complement-Activating Capacities of Therapeutic Antibodies – Impact of CD55 Expression on the Mode of Action

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only